top of page
Search
  • Writer's pictureThe San Juan Daily Star

Clinical study offers innovative treatment opportunity to patients with decompensated cirrhosis


Decompensated cirrhosis is a chronic and irreversible disease of the liver that can have serious health consequences.

By The Star Staff


FDI Clinical Research announced that it is recruiting patients with decompensated cirrhosis to participate in the clinical study of an innovative treatment that seeks to combat the damage caused by this condition.


“At FDI Clinical Research, we are committed to developing treatments that improve the quality of life for those suffering from decompensated cirrhosis. Our team of researchers is conducting clinical studies that seek to develop therapies that manage to reverse some of the damage caused by this condition, until now considered irreversible,” explained Dr. José Rodríguez Orengo, CEO of FDI Clinical Research.


For her part, Dr. Vivian Tamayo, researcher in the study, highlighted the importance of recruiting patients with decompensated cirrhosis to advance in the knowledge and treatment of this disease.


“This study represents a unique opportunity to contribute to the advancement of science in the management of decompensated cirrhosis. We are looking for brave and committed individuals who wish to participate in finding innovative solutions for this condition,” she said.


Decompensated cirrhosis is a chronic and irreversible disease of the liver that can have serious health consequences. Complications that may include clotting problems, excessive fluid accumulation in the abdomen (ascites), bleeding from varicose veins of the esophagus, and hepatic encephalopathy.


“If you are a person suffering from decompensated cirrhosis, we invite you to consider this valuable opportunity to contribute to medical science and potentially improve your quality of life. At FDI Clinical Research, we strive to provide a safe environment for our patients, and we ensure confidentiality and ethics in all of our research,” said Dr. Tamayo.


Those interested in participating in the study should contact FDI Clinical Research at (787) 722-1248.

18 views0 comments

Comments


bottom of page